Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, Boice JD Jr, Shore RE; Women's Environment, Cancer and Radiation Epidemiology Study Collaborative Group; Bernstein JL. Bertelsen L, et al. Among authors: ejlertsen b. J Natl Cancer Inst. 2008 Jan 2;100(1):32-40. doi: 10.1093/jnci/djm267. Epub 2007 Dec 25. J Natl Cancer Inst. 2008. PMID: 18159070
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL. Ejlertsen B, et al. J Clin Oncol. 2006 Nov 1;24(31):4956-62. doi: 10.1200/JCO.2005.05.1235. J Clin Oncol. 2006. PMID: 17075113 Clinical Trial.
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P, Ewertz M, Kamby C, Lindman H, Nordenskjöld B, Bergh J. Kristensen B, et al. Among authors: ejlertsen b. Acta Oncol. 2008;47(4):740-6. doi: 10.1080/02841860801964988. Acta Oncol. 2008. PMID: 18465343 Clinical Trial.
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT. Lykkesfeldt AE, et al. Among authors: ejlertsen b. BMC Cancer. 2009 Jun 16;9:185. doi: 10.1186/1471-2407-9-185. BMC Cancer. 2009. PMID: 19531212 Free PMC article. Clinical Trial.
271 results